Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?

• References

• 1 Franchini M, Coppola A, Rocino A , et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39 (7) 752-766
• 2 Arruda MA. No evidence of efficacy or evidence of no efficacy. JAMA Pediatr 2013; 167 (3) 300-302
• 3 Messori A, Fadda V, Maratea D, Trippoli S. Erythropoietin in patients with acute myocardial infarction: no proof of effectiveness or proof of no effectiveness?. Clin Cardiol 2013; 36 (10) E39-E40
• 4 Messori A, Fadda V, Maratea D, Trippoli S. Erythropoiesis-stimulating agents in heart failure: no proof of effectiveness or proof of no effectiveness?. Eur J Heart Fail 2013; 15 (8) 944-945
• 5 Messori A, Fadda V, Maratea D, Trippoli S. ω-3 fatty acid supplements for secondary prevention of cardiovascular disease: from “no proof of effectiveness” to “proof of no effectiveness”. JAMA Intern Med 2013; 173 (15) 1466-1468
• 6 Ahn S, Park SH, Lee KH. How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology 2013; 267 (2) 328-338
• 7 Hausleiter J, Meyer TS, Martuscelli E , et al. Image quality and radiation exposure with prospectively ECG-triggered axial scanning for coronary CT angiography: the multicenter, multivendor, randomized PROTECTION-III study. JACC Cardiovasc Imaging 2012; 5 (5) 484-493